Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency (SCID). According to Globaldata, it is involved in 18 clinical trials, of which 3 were completed, 11 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Briquilimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Briquilimab is expected to reach an annual total of $24 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Briquilimab Overview
Briquilimab (AMG-191) is under development for the treatment of fanconi anemia, myelodysplastic syndrome, severe combined immunodeficiency, sickle cell disease, chronic granulomatous disease (CGD), chronic inducible urticaria (CIndU), passive systemic anaphylaxis, cockroach allergen induced allergic asthma, atopic dermatitis and chronic spontaneous urticaria (CSU). The drug candidate acts by targeting stem cell growth factor receptor Kit. It is a humanized anti-c-Kit monoclonal antibody. It is administered through intravenous route and subcutaneous route.
It was also under development for the treatment of Gaucher disease type 1, acute myeloid leukemia and inflammatory diseases such as idiopathic pulmonary fibrosis (IPF).
Jasper Therapeutics Overview
Jasper Therapeutics is a biotechnology company that develops antibodies for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate-risk myelodysplastic syndromes (MDS). It operates as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). It develops and commercializes stem cell engineering for expanded use of stem cell transplantation. The company pipeline products are JSP191 is in clinical development that clears hematopoietic stem cells from bone marrow. It also offers engineered hematopoietic stem cells(eHSCs) platform to address the limitations of transplant grafts and unlock the potential of stem cells. Jasper Therapeutics is headquartered in ReedWood, California, the US.
The operating loss of the company was US$68.9 million in FY2023, compared to an operating loss of US$51.2 million in FY2022. The net loss of the company was US$64.5 million in FY2023, compared to a net loss of US$37.7 million in FY2022.
For a complete picture of Briquilimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
